| Literature DB >> 11449330 |
H Sandberg1, A Almstedt, J Brandt, V M Castro, E Gray, L Holmquist, M Lewin, U Oswaldsson, M Mikaelsson, M A Jankowski, M Bond, H A Scoble.
Abstract
A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been deleted. To ensure that BDDrFVIII contains the requisite structural and functional features, it has been subjected to detailed biochemical and biophysical characterization in comparison to the plasma-derived form of factor VIII. Laboratory studies have shown that the primary, secondary, and tertiary structures of BDDrFVIII and the posttranslational modifications are similar to those of the [80 + 90]-kd form of plasma-derived factor VIII. In addition, BDDrFVIII has full biologic activity compared with full-length factor VIII preparations.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11449330 DOI： 10.1016/s0037-1963(01)90103-9
Source DB: PubMed Journal: Semin Hematol ISSN： 0037-1963 Impact factor: 3.851